Meeting
2020 Genitourinary Cancers Symposium
Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.
Authors
Howard M. Sandler
Cedars-Sinai Medical Center, Los Angeles, CA
Howard M. Sandler , Theodore Karrison , A. Oliver Sartor , Leonard G. Gomella , Mahul B. Amin , James Purdy , Jeff M. Michalski , Mark Garzotto , Nadeem Pervez , Alexander G. Balogh , George Rodrigues , Luis Souhami , M. Neil Reaume , Scott Williams , Raquibul Hannan , Christopher U. Jones , Eric M. Horwitz , Joseph P. Rodgers , Felix Y Feng , Seth A. Rosenthal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT00288080
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 333)
Abstract #
333
Poster Bd #
M17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
First Author: Ryan Phillips
Poster
2015 Genitourinary Cancers Symposium
A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity.
First Author: Joan Carles
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed
Poster
2022 ASCO Genitourinary Cancers Symposium
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
First Author: Sean Matthew McBride